GNFT (GNFT)

Genfit S.A. is a biopharmaceutical company focused on developing treatments for metabolic and liver diseases. Their pipeline includes drug candidates and diagnostic solutions for conditions like primary biliary cholangitis and NASH.

46/100 AI Score MCap 398M Vol 564

Company Overview

CEOM. Pascal Prigent
Employees180
HeadquartersLoos, FR
IPO Year2019

Genfit S.A. pioneers innovative therapies for liver and metabolic diseases, highlighted by its late-stage Elafibranor and diagnostic solutions like NIS4, positioning it as a key player in addressing unmet needs within a rapidly growing market and creating significant value for investors.

Investment Thesis

Genfit presents a compelling investment opportunity due to its focus on high-growth markets within liver and metabolic diseases. The potential approval and commercialization of Elafibranor for PBC represents a significant near-term value driver. Furthermore, the development and commercialization of NIS4 technology for NASH diagnosis could capture a substantial share of the growing diagnostic market. The company's strategic partnerships, such as the one with Labcorp, enhance its commercialization capabilities and reduce risk. With a market capitalization of $0.37 billion and a gross margin of 93.1%, Genfit offers significant upside potential if its key pipeline assets achieve regulatory approval and market adoption. The company's focus on innovative solutions and strategic collaborations positions it for long-term growth and value creation.

Key Highlights

  • Elafibranor is in Phase 3 clinical trials for primary biliary cholangitis (PBC), representing a potential near-term catalyst.
  • NIS4 technology is under development for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis, addressing a significant unmet need.
  • Gross margin of 93.1% indicates strong potential profitability upon commercialization of key assets.
  • Strategic licensing agreement with Labcorp for NASHnext enhances commercialization capabilities.
  • GNS561 is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA), expanding the pipeline into additional indications.

Competitors

Strengths

  • Strong pipeline of drug candidates and diagnostic solutions.
  • Strategic partnerships with leading companies.
  • Expertise in metabolic and liver diseases.
  • High gross margin potential.

Weaknesses

  • Reliance on successful clinical trial outcomes.
  • Negative profit margin.
  • Limited commercialization infrastructure.
  • Dependence on partnerships for commercial success.

Catalysts

  • Upcoming: Elafibranor Phase 3 clinical trial results for PBC.
  • Upcoming: Regulatory approval decisions for Elafibranor.
  • Ongoing: Development and commercialization of NIS4 technology for NASH diagnosis.
  • Ongoing: Advancement of GNS561 into later-stage clinical trials for CCA.
  • Ongoing: New strategic partnerships and licensing agreements.

Risks

  • Potential: Clinical trial failures for key drug candidates.
  • Potential: Regulatory delays or rejection of drug candidates.
  • Ongoing: Competition from other biotechnology companies.
  • Ongoing: Dependence on partnerships for commercial success.
  • Potential: Negative profit margin and need for additional financing.

Growth Opportunities

  • Elafibranor Approval and Commercialization: The successful completion of Phase 3 trials and subsequent regulatory approval of Elafibranor for PBC represents a significant growth opportunity. The PBC market is underserved, and Elafibranor could become a leading treatment option, driving substantial revenue growth for Genfit. The timeline for potential approval is estimated within the next 1-2 years, pending clinical trial results and regulatory review.
  • NASH Diagnostic Market Penetration with NIS4: The development and commercialization of NIS4 technology for NASH diagnosis offers a substantial growth opportunity. The NASH diagnostic market is rapidly expanding, driven by the increasing prevalence of the disease. NIS4 has the potential to become a leading non-invasive diagnostic tool, capturing a significant share of this market. The timeline for commercialization is estimated within the next 2-3 years, pending clinical validation and regulatory approval.
  • Expansion of GNS561 into Cholangiocarcinoma Treatment: The advancement of GNS561 into later-stage clinical trials for cholangiocarcinoma (CCA) represents a growth opportunity. CCA is a rare but aggressive cancer with limited treatment options, creating a high unmet need. Successful development and commercialization of GNS561 could generate significant revenue for Genfit. The timeline for potential approval is estimated within the next 3-5 years, pending clinical trial results and regulatory review.
  • Strategic Partnerships and Licensing Agreements: Genfit's strategy of forming strategic partnerships and licensing agreements, such as the one with Labcorp, provides a growth opportunity by expanding its commercial reach and capabilities. These partnerships can accelerate the development and commercialization of its products, reducing risk and maximizing market penetration. Ongoing collaborations and new partnerships will continue to drive growth.
  • Expansion into New Indications and Therapeutic Areas: Genfit has the opportunity to leverage its expertise and technology platform to expand into new indications and therapeutic areas within metabolic and liver diseases. This could involve developing new drug candidates or diagnostic solutions for conditions such as acute-on-chronic liver failure or other related disorders. This diversification strategy can mitigate risk and create new avenues for growth.

Opportunities

  • Expansion into new indications and therapeutic areas.
  • Increased adoption of non-invasive diagnostic tools.
  • Growing prevalence of NASH and PBC.
  • Potential for breakthrough therapies in underserved markets.

Threats

  • Regulatory hurdles and delays.
  • Competition from other biotechnology companies.
  • Clinical trial failures.
  • Pricing pressures from payers.

Competitive Advantages

  • Proprietary drug candidates and diagnostic technologies.
  • Strong intellectual property protection.
  • Strategic partnerships with leading pharmaceutical and diagnostic companies.
  • Expertise in metabolic and liver diseases.

About

Genfit S.A., founded in 1999 and headquartered in Loos, France, is a biopharmaceutical company dedicated to discovering and developing innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases. The company's mission is to address significant unmet medical needs in areas such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and cholangiocarcinoma (CCA). Genfit's lead product candidate, Elafibranor, is currently in Phase 3 clinical trials for the treatment of PBC. Additionally, Genfit is developing NIS4 technology for the diagnosis of NASH and fibrosis, aiming to provide a non-invasive diagnostic tool for early detection and monitoring of the disease. The company is also advancing GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA), and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. Genfit has established strategic collaborations, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test, and with Genoscience Pharma to develop and commercialize GNS561 for CCA. These partnerships are crucial for expanding the reach and impact of Genfit's innovative solutions in the market.

What They Do

  • Develop drug candidates for metabolic diseases.
  • Develop drug candidates for liver-related diseases.
  • Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
  • Develop diagnostic solutions for liver diseases like NASH.
  • Seek regulatory approval for drug candidates and diagnostic solutions.
  • Commercialize approved products through partnerships and direct sales.

Business Model

  • Develop and out-license drug candidates to larger pharmaceutical companies.
  • Generate revenue through licensing agreements and royalties.
  • Commercialize diagnostic solutions directly or through partnerships.
  • Receive milestone payments upon achieving clinical and regulatory milestones.

Industry Context

Genfit operates in the biotechnology sector, specifically targeting the metabolic and liver disease market. This market is characterized by high unmet needs and significant growth potential, driven by factors such as increasing prevalence of NASH and PBC. The competitive landscape includes companies like ARMP, EPRX, IVA, IVVD, and MDWD, all vying to develop innovative therapies and diagnostics. Genfit's focus on NASH and PBC, coupled with its diagnostic solutions, positions it to capture a share of this expanding market. The global NASH market, for example, is projected to reach billions of dollars in the coming years, presenting a substantial opportunity for Genfit.

Key Customers

  • Patients with metabolic and liver-related diseases.
  • Physicians who treat patients with these diseases.
  • Diagnostic laboratories that use diagnostic solutions.
  • Pharmaceutical companies that license drug candidates.
AI Confidence: 72% Updated: 2/9/2026

Financials

Chart & Info

Price Chart

GNFT (GNFT) stock price: $8.00 (+0.58, +7.82%)

Why Bull

  • •AI analysis temporarily unavailable
  • •Check back shortly for updated insights
  • •Market sentiment data being refreshed
  • •Community discussions being analyzed

Why Bear

  • •AI analysis temporarily unavailable
  • •Check back shortly for updated insights
  • •Risk factors being evaluated
  • •Market concerns being processed

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
564

Rationale

AI-generated technical analysis for GNFT including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss GNFT (GNFT) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for GNFT.

Make a Prediction

Set your price target for GNFT (GNFT), choose a timeframe, and track your prediction accuracy.

Current price: $8.00

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNFT.

Price Targets

Wall Street price target analysis for GNFT.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

45.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 5/100

    Gross margin data is currently unavailable for this company.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates GNFT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Genfit S.A. do?

Genfit S.A. is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions for metabolic and liver-related diseases. Their primary focus is on addressing unmet medical needs in areas such as nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). The company's lead product candidate, Elafibranor, is in Phase 3 clinical trials for PBC. Genfit also develops diagnostic technologies like NIS4 for NASH. They aim to improve patient outcomes through innovative therapies and diagnostic tools, commercializing either independently or through strategic partnerships.

Is GNFT stock a good buy?

GNFT stock's potential as a good buy hinges on the successful development and commercialization of its pipeline assets, particularly Elafibranor. While the company has a high gross margin of 93.1%, it currently operates with a negative profit margin. Positive clinical trial results and regulatory approvals could significantly increase its value. Investors should carefully consider the risks associated with biotechnology investments, including clinical trial failures and regulatory hurdles. A balanced analysis of its growth potential and financial stability is crucial before investing.

What are the main risks for GNFT?

The main risks for Genfit S.A. include the potential failure of its key drug candidates in clinical trials, which could significantly impact its valuation. Regulatory hurdles and delays in obtaining approvals for its products also pose a risk. The company faces competition from other biotechnology companies developing similar therapies. Additionally, Genfit's reliance on partnerships for commercialization exposes it to risks associated with the performance and strategic decisions of its partners. The company's negative profit margin and need for additional financing also present financial risks.

Is GNFT a good stock to buy?

Whether GNFT is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the GNFT MoonshotScore?

The MoonshotScore for GNFT is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is GNFT data updated?

GNFT stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to GNFT is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for GNFT?

Growth catalysts for GNFT (GNFT) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes GNFT's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are GNFT's main competitors?

GNFT (GNFT) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether GNFT has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about GNFT?

Wall Street analyst coverage for GNFT includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is GNFT's market cap?

Market capitalization (market cap) for GNFT is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows GNFT's current market cap alongside enterprise value and other valuation metrics.

How has GNFT stock performed recently?

GNFT's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing GNFT's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in GNFT?

Key risk categories for GNFT include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures GNFT's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling GNFT?

Insider trading activity for GNFT tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is GNFT a good stock for beginners?

GNFT (GNFT) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is GNFT for first-time investors?

Every stock carries risk, including GNFT (GNFT). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like GNFT.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on available data and may be subject to change.
  • Investment decisions should be made based on individual risk tolerance and financial circumstances.
Data Sources
profilefundamentalsexistingCopy